[CAS NO. 366-70-1] ProcarbazineHydrochloride
PRODUCTS SPECIFICATIONS [366-70-1]
DESCRIPTION [366-70-1]
Overview
| MDL | MFCD00072082 |
|---|---|
| Molecular Weight | 257.76 |
| Molecular Formula | C12H20ClN3O |
| SMILES | O=C(NC(C)C)C1=CC=C(CNNC)C=C1.Cl |
2 Publications Citing Use of MCE
Summary
In Vitro
Procarbazine Hydrochloride (5 and 20 nM; 1 h) treatment shows cell survival at various concentrarions [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | L1210 cells |
| Concentration: | 5 and 20 nM |
| Incubation Time: | 1 hour |
| Result: | Showed 99.3% and 99.9% survival of cells at 5 mM and 20 mM, respectively. |
In Vivo
Procarbazine (Intraperitoneal injection; 50 and 150 mg/kg; once daily; 5 d) induces micronuclei in hematopoietic cells, but not increases the lacZ mutant frequency (MF) in bone marrow [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male muta mouse (7–8 weeks old) [2] |
| Dosage: | 50 and 150 mg/kg |
| Administration: | Intraperitoneal injection; 50 and 150 mg/kg; once daily; 5 days |
| Result: | Increased the MN frequency appreciably, and observed micronucleus induction in the peripheral blood at 50 mg/kg. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00002944 | Children´s Oncology Group|National Cancer Institute (NCI) |
Brain Tumors|Central Nervous System Tumors
|
April 1997 | Phase 3 |
| NCT00003293 | Pfizer |
Brain and Central Nervous System Tumors
|
February 1998 | Phase 3 |
| NCT00002463 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
February 1989 | Phase 2 |
| NCT02661503 | University of Cologne |
Classical Hodgkin Lymphoma
|
July 2016 | Phase 3 |
| NCT00049439 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
March 1998 | Phase 2 |
| NCT00417014 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Lymphoma
|
Not Applicable | |
| NCT00003929 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 1998 | Phase 2 |
| NCT00887146 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|European Organisation for Research and Treatment Center (EORTC)|Canadian Cancer Trials Group |
Brain and Central Nervous System Tumors
|
September 2009 | Phase 3 |
| NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
April 2, 2012 | Phase 2 |
| NCT00002840 | European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council |
Brain and Central Nervous System Tumors
|
August 1996 | Phase 3 |
| NCT00335140 | Eastern Cooperative Oncology Group |
Lymphoma
|
December 2006 | Phase 2 |
| NCT00265031 | University of Cologne |
Hodgkin´s Lymphoma
|
January 1999 | Phase 3 |
| NCT00678327 | University College, London|Cancer Research UK|Cancer Research UK & UCL Cancer Trials Centre |
Lymphoma
|
August 29, 2008 | Phase 3 |
| NCT00577993 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 16, 1998 | Phase 3 |
| NCT00989352 | University Hospital Freiburg|Universitätsklinikum Köln|Ludwig-Maximilians - University of Munich|University Hospital Heidelberg|University Hospital Ulm |
Primary Non Hodgkin Lymphoma of the Central Nervous System
|
September 2009 | Phase 2 |
| NCT00416832 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
November 2002 | Phase 2 |
| NCT01251107 | Fondazione Michelangelo |
Hodgkin Lymphoma
|
March 2000 | Phase 3 |
| NCT00433459 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
January 2007 | Phase 3 |
| NCT02298283 | The Lymphoma Academic Research Organisation |
Hodgkin Lymphoma
|
April 2015 | Phase 2 |
| NCT00734773 | Northwestern University|Pharmacyclics LLC. |
Brain and Central Nervous System Tumors|Lymphoma|Neurotoxicity
|
November 2008 | Early Phase 1 |
| NCT00002462 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
September 1989 | Phase 3 |
| NCT00003375 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|North Central Cancer Treatment Group|Eastern Cooperative Oncology Group|NRG Oncology |
Brain and Central Nervous System Tumors
|
October 1998 | Phase 2|Phase 3 |
| NCT05008224 | Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma
|
October 7, 2021 | Phase 2 |
| NCT00416377 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Lymphoma
|
Not Applicable | |
| NCT00003114 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
July 1997 | Phase 2 |
| NCT00079105 | Newcastle-upon-Tyne Hospitals NHS Trust |
Lymphoma
|
January 2004 | Phase 2 |
| NCT00379041 | European Organisation for Research and Treatment of Cancer - EORTC |
Lymphoma
|
September 1, 1993 | Phase 3 |
| NCT03495960 | International Extranodal Lymphoma Study Group (IELSG) |
Primary Central Nervous System Lymphoma
|
June 15, 2019 | Phase 2 |
| NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. |
HIV-associated Hodgkin Lymphoma
|
March 2004 | Phase 2 |
| NCT01775475 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma
|
September 15, 2016 | Phase 2 |
| NCT00049595 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l´Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group |
Lymphoma
|
August 2002 | Phase 3 |
| NCT00003564 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
Phase 3 | |
| NCT00574496 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
November 13, 2007 | Phase 2 |
| NCT00002569 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Southwest Oncology Group|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group |
Brain and Central Nervous System Tumors
|
July 1994 | Phase 3 |
| NCT00264953 | University of Cologne |
Hodgkin´s Lymphoma
|
May 1998 | Phase 3 |
| NCT00005796 | Indiana University|Indiana University Melvin and Bren Simon Cancer Center |
Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug+Agent Toxicity by Tissue+Organ
|
February 2000 | Phase 1 |
| NCT00666484 | University College, London |
Lymphoma|Neurotoxicity
|
March 2008 | Phase 2 |
| NCT00187057 | St. Jude Children´s Research Hospital|Children´s Hospital of Philadelphia|National Cancer Institute (NCI) |
Ataxia-Telangiectasia
|
September 2002 | Not Applicable |
| NCT00079092 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
January 1, 2004 | Phase 2 |
| NCT01569204 | University of Cologne |
Hodgkin Lymphoma
|
October 2012 | Phase 2 |
| NCT00002806 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
July 1996 | Phase 2 |
| NCT00822120 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Nonneoplastic Condition
|
July 2009 | Phase 2 |
| NCT01132807 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2010 | Phase 2 |
| NCT00003421 | Medical Research Council|National Cancer Institute (NCI) |
Lymphoma
|
June 1998 | Phase 3 |
| NCT01399372 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity
|
September 2011 | Phase 2 |
| NCT00004004 | New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
July 1999 | Phase 1|Phase 2 |
| NCT00052455 | Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
October 2002 | Phase 3 |
| NCT02315326 | Memorial Sloan Kettering Cancer Center|Pharmacyclics LLC.|Janssen Biotech, Inc. |
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)|Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
December 2014 | Phase 1|Phase 2 |
| NCT00003113 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
July 1997 | Phase 2 |
| NCT00003788 | Colorado Health Foundation|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
April 1998 | Phase 3 |
| NCT00003101 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors
|
August 1997 | Phase 2 |
| NCT00503594 | Assistance Publique - Hôpitaux de Paris|French Innovative Leukemia Organisation |
Lymphoma
|
July 2007 | Phase 2 |
| NCT00004010 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
| NCT01737346 | Incheon St.Mary´s Hospital|National Cancer Center, Korea |
Recurrent Glioblastoma Multiforme
|
October 2012 | Phase 2 |
| NCT00074191 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
| NCT00025064 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 100 mg/mL ( 387.96 mM ; Need ultrasonic)
DMSO : 16.67 mg/mL ( 64.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.8796 mL | 19.3979 mL | 38.7958 mL |
| 5 mM | 0.7759 mL | 3.8796 mL | 7.7592 mL |
| 10 mM | 0.3880 mL | 1.9398 mL | 3.8796 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (387.96 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.67 mg/mL (6.48 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.67 mg/mL (6.48 mM); Clear solution
References
- [1] J M Erikson, et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res. 1989 Jan 1;49(1):127-33.
- [2] T Suzuki, et al. Procarbazine genotoxicity in the MutaMouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res. 1999 Aug 18;444(2):269-81.
Synonyms